Medical Cannabis

A review of the literature to examine the analgesic properties of cannabis.

What changes need to be adopted in our industry to make the transition to the pharmaceutical industry testing paradigm?

GW Pharmaceuticals recently announced the company’s financial results from the second quarter of 2019.

Big Pharma is working on locking up cannabis patents, creating partnerships, and standing by to use its financial muscle for more ownership of the medical cannabis industry when the time is right.

Lesser known cannabinoids and terpenes may be helpful for patients. Here the author shows why, and how patients can choose more effective medical cannabis products.

By understanding whole-plant extractions better, businesses will be able to better plan for long-term profitability and sustainability.  

David L. Nathan, MD, DFAPA, President, Board of Directors, Doctors for Cannabis Regulations (DFCR), discusses how the DFCR was formed, the efforts they have been making in the cannabis field, and plans for the future of the organization.

In honor of National Women’s Month, Josh Crossney highlights some of the amazing women that will be speaking at the first Cannabis Science Conference East show.

Ricki Lake discusses returning to Baltimore to speak at CSC East and her award-winning documentary, Weed the People.

Here we take a closer look at Australia’s medical cannabis program, the laws surrounding it, and speak to Australian pharmacist Paul Mavor.

Dr. Ethan Russo, Director of Research and Development for the International Cannabis and Cannabinoids Institute (ICCI), recently spoke with us about some of his recent research efforts, cannabis dosing, and his continued push to change the stigma against cannabis as a medicine.

Paul Mavor, an Australian and UK licensed pharmacist and the CEO and Founder of Health House International, recently spoke to us about Australia’s medical cannabis program, the testing and regulations in place, and the future outlook for cannabis in his country.

The New Zealand government passed a law on December 11, 2018, that will establish a regulated medical cannabis scheme within one year.

George Anastassov, the CEO of AXIM Biotech, recently spoke to us about the current good manufacturing methods (cGMPs) his company has developed, their significance to the market, and plans for the future.

An interview with Sue Sisley

An interview with Montel Williams

An interview with Uma Dhanabalan

An interview with Susan Audino

An interview with Jeffrey C. Raber

Giuseppe Cannazza and Cinzia Citti from the University of Modena and Reggio Emilia discuss the growing interest in the use of medicinal cannabis in Europe and the analytical challenges involved.